– Zolbetuximab is currently the first and only therapy approved in the European Union to target claudin 18.2, a biomarker positively expressed by 38% of patients with advanced gastric cancer1,2 – Treatment with the claudin 18.2-targeted monoclonal antibody shown to significantly extend…